Six States Set Records for COVID-19 Hospitalizations
Wyoming’s 36.7 percent increase since last week in its rolling seven-week average was the largest of any state
Respiratory Infections
Sisunatovir Fast-Tracked for Serious RSV Infection
Sisunatovir is an orally administered RSV fusion inhibitor that binds to RSV-F protein on the viral surface inhibiting RSV replication.
Risk for COVID-19 Increased for Adults Taking PPIs
Dose-response relationship observed; risk up 3.67-fold for those using PPIs up to twice daily.
MPR Weekly Dose Podcast Episode 37
This week on the pod we look at results from a COVID-19 prevention trial of hydroxychloroquine; A vaccine arrival date prediction by Dr Fauci; A FDA notification regarding vial caps; A look into prescription patterns during COVID-19; And an antibody treatment trial begins.
Review Highlights Neuropsychiatric Presentations of COVID-19
Evidence presented for delirium during COVID-19, post-illness neuropsychiatric consequences for SARS, MERS
Investigational RSV Vaccine Gets Fast Track Status
An investigational vaccine to protect against respiratory syncytial virus (RSV) infection has received Fast Track designation from the Food and Drug Administration (FDA).
Vanco Ready Now Available in Four, Ready-to-Use Doses
Vanco Ready, a ready-to-use (RTU) vancomycin injection, has been made available by Xellia Pharmaceuticals. The new 100mL premixed bag contains 500mg of vancomycin and is stable at room temperature (up to 25 °C) with a 16-month shelf life in overwrap and 28-day shelf life outside of overwrap. The product can also be stored in automated…
Stewardship Intervention Can Cut Inappropriate Rx by a Third
Findings observed for acute respiratory infection in emergency departments and urgent care centers
Pertussis Risk Up for Undervaccinated, Unvaccinated Children
However, most pertussis cases occur among vaccinated children further away from last DTaP dose
FDA Warns of Unapproved, Misbranded Drugs Distributed by CanaRx to US Consumers
The Food and Drug Administration (FDA) has issued a warning letter to CanaRx, a company operating as a prescription drug provider, for its involvement in the distribution of certain unapproved or misbranded drugs that may be harmful to US consumers.
